Photo taken from Lung Cancer Europe/LinkedIn
May 5, 2024, 12:19
Lung Cancer Europe – Alk Ros1 France Cancer Poumon has become a member of Lung Cancer Europe
Lung Cancer Europe shared a post on LinkedIn:
“NEW LuCE MEMBER: Alk+ France cancer poumon
We are very happy that Alk Ros1 France Cancer Poumon has become a member of Lung Cancer Europe (LuCE).
Alk+ France cancer poumon is a group of patients affected by lung cancer with ALK or ROS1 rearrangement, rare pathologies representing 1 to 5% of non-small cell lung cancers (NSCLC).
Their objectives are to:
- Raise awareness of these rare and little-known forms of lung cancer
- Support patients in their care journey and inform them about the disease
- Interact with healthcare professionals specializing in the field to stay informed of the best available and upcoming therapeutic options
- Encourage research into the development of new treatments, synonymous with hope and quality of life
- Represent ALK and ROS1 patients in professional and decision-making bodies and ensure that everyone has access to the latest therapeutic advances regardless of their geographical position in the territory
- Raise funds to achieve our objectives, finance communications tools and activities for the benefit of patients.They have approximately 300 members including:
- Valerie Montagny – President
- Sandrina Alliaume – Secretary
- Anne Laurence Coursier and Adeline Chocarelle – International Relations TeamWe take great pride in welcoming them and their members to LuCE and look forward to working with the organisation on all of our shared objectives.”
Source: Lung Cancer Europe/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19
Dec 21, 2024, 19:18
Dec 21, 2024, 18:59
Dec 21, 2024, 18:57
Dec 21, 2024, 18:54